Summary
Timothy A Stewart (born 30 September 1952) is a molecular biologist. He graduated from the University of Otago (BScHons, PhD.)
Stewart was born in Christchurch, New Zealand. He was a pioneer in the technique of transferring recombinant genes to mice (transgenic mice) and in 1988 he and Philip Leder were granted a patent on a genetically engineered mammal. This "oncomouse" patent was the first to be issued covering a higher life form.[1]
From 1984 to 2003 Stewart was a scientist at Genentech where he developed the concept that the type I interferons might be a significant component in the initiation or progression of type I diabetes.[2]
He has published 61 peer reviewed papers listed in Scopus; the most highly cited has 1013 citations to it,[3] and he has 31 papers with 34 citations or more.
References edit
- ^ Oncomouse
- ^ Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases. Stewart TA Cytokine Growth Factor Rev. 2003 Apr;14(2):139–54.
- ^ Flynn, J L; Chan, J; Triebold, K J; Dalton, D K; Stewart, T A; Bloom, B R (1993). "An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection". Journal of Experimental Medicine. 178 (6): 2249–2254. doi:10.1084/jem.178.6.2249. ISSN 0022-1007. PMC 2191274.